|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 64.59 USD | -1.79% |
|
-3.21% | +1.65% |
| 04-08 | Cytokinetics Insider Sold Shares Worth $292,985, According to a Recent SEC Filing | MT |
| 03-19 | Mizuho Raises Price Target on Cytokinetics to $100 From $84, Keeps Outperform Rating | MT |
| Capitalization | 7.96B 6.8B 6.29B 5.93B 11B 735B 11.25B 74.2B 28.93B 355B 29.85B 29.22B 1,266B | P/E ratio 2026 * |
-9.98x | P/E ratio 2027 * | -13.6x |
|---|---|---|---|---|---|
| Enterprise value | 7.76B 6.64B 6.13B 5.78B 10.73B 717B 10.98B 72.42B 28.24B 346B 29.14B 28.52B 1,236B | EV / Sales 2026 * |
84x | EV / Sales 2027 * | 20.3x |
| Free-Float |
98.67% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Cytokinetics, Incorporated
| 1 day | -1.79% | ||
| 1 week | -3.21% | ||
| Current month | -2.00% | ||
| 1 month | +3.48% | ||
| 3 months | +3.33% | ||
| 6 months | +7.10% | ||
| Current year | +1.65% |
| 1 week | 64.21 |  | 67.77 |
| 1 month | 58.43 | | 68.71 |
| Current year | 58.43 | | 70.39 |
| 1 year | 29.31 | | 70.98 |
| 3 years | 25.98 | | 110.25 |
| 5 years | 17.72 | | 110.25 |
| 10 years | 5.75 | | 110.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Blum
CEO | Chief Executive Officer | 62 | 31/12/2006 |
Sung Lee
DFI | Director of Finance/CFO | 56 | 07/05/2024 |
Kari Loeser
CMP | Compliance Officer | - | 31/10/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Blum
BRD | Director/Board Member | 62 | 31/12/2006 |
John Henderson
CHM | Chairman | 81 | 07/04/2022 |
Wendell Wierenga
BRD | Director/Board Member | 78 | 08/02/2011 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.79% | -3.21% | +73.07% | +77.35% | 7.96B | |
| +1.92% | +6.29% | +41.21% | +99.19% | 49.22B | |
| +2.36% | +2.91% | +107.20% | +26.69% | 46.83B | |
| -0.37% | -1.75% | +136.25% | +848.25% | 34.45B | |
| -0.11% | +0.88% | -2.29% | -28.64% | 23.26B | |
| +1.01% | +2.05% | +86.78% | -28.20% | 18.77B | |
| +0.49% | +3.43% | +48.85% | -31.74% | 17.32B | |
| +1.99% | +0.51% | +86.38% | +202.08% | 15.93B | |
| +2.66% | -0.36% | +5.92% | +1,162.09% | 14.97B | |
| +1.61% | +1.23% | +75.57% | - | 14.44B | |
| Average | +0.97% | +0.19% | +65.90% | +258.56% | 24.32B | |
| Weighted average by Cap. | +1.22% | +1.11% | +71.16% | +239.79% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 92.44M 79.01M 73.04M 68.86M 128M 8.54B 131M 862M 336M 4.12B 347M 340M 14.71B | 371M 317M 293M 277M 513M 34.3B 525M 3.46B 1.35B 16.55B 1.39B 1.36B 59.09B |
| Net income | -820M -701M -648M -611M -1.13B -75.79B -1.16B -7.65B -2.98B -36.56B -3.08B -3.01B -131B | -643M -550M -508M -479M -889M -59.44B -910M -6B -2.34B -28.67B -2.41B -2.36B -102B |
| Net Debt | -191M -163M -151M -142M -264M -17.64B -270M -1.78B -694M -8.51B -716M -701M -30.38B | -421M -360M -333M -314M -582M -38.93B -596M -3.93B -1.53B -18.78B -1.58B -1.55B -67.06B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/04/26 | 64.59 $ | -1.79% | 1,364,665 |
| 08/04/26 | 65.77 $ | +0.44% | 1,755,975 |
| 07/04/26 | 65.48 $ | +0.83% | 1,327,626 |
| 06/04/26 | 64.94 $ | -2.68% | 1,314,251 |
| 02/04/26 | 66.73 $ | +0.18% | 2,479,314 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- CYTK Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition